Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus AG as first-line therapy in advanced cholangiocarcinoma
ChiCTR2100044170Phase 4Recruiting
- Sponsor
- Anqing City Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in cholangiocarcinoma (CCA), sponsored by Anqing City Hospital. Primary endpoint: Progression-free survival (PFS). Started May 2021; status: recruiting.
02
Drugs
anlotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100044170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044170.